USA flag logo/image

An Official Website of the United States Government

Development of a Novel Anti-HIV Oligonucleotide

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
29153
Program Year/Program:
1995 / SBIR
Agency Tracking Number:
29153
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Triplex Pharmaceutical
9391 Grogans Mill Road The Woodlands, TX 77380
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1995
Title: Development of a Novel Anti-HIV Oligonucleotide
Agency: HHS
Contract: 1 R43 AI38788-01,
Award Amount: $98,800.00
 

Abstract:

AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haanti-HIV activity. We will perform preclinical animal pharmacology studies, including pharmacokinetiand toxicity studies in mice. One of these aims includes investigating a novel in vivo route of admioligonucleotides. Although there are a number of drugs that are currently available for the treatmenhave limited effectiveness and only delay the progression to death of AIDS patients. There is a greadevelopment of more effective and novel drugs for the treatment of AIDS. T30177 may provide significpresently available HIV drugs because it has a novel mechanism of action, it is active against AZT-rbeen shown in pilot animal studies to have a long half-life, good stability, and low toxicity.

Principal Investigator:

Thomas Wallace
71363

Business Contact:

Small Business Information at Submission:

Triplex Pharmaceutical
9391 Grogans Mill Road The Woodlands, TX 77380

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No